Navigation Links
Optimer Pharmaceuticals to Present at the Canaccord Genuity Annual Growth Conference

SAN DIEGO, Aug. 1, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that the Company will present at the Canaccord Genuity Annual Growth Conference on August 10, 2011 at 11:30 a.m. Eastern Time at the InterContinental Hotel in Boston.


A live audio webcast of this presentation will be accessible in the Investors section of the Company's website at Replays of this presentation will be available at the same location for 30 days following the meeting.

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer developed and is commercializing DIFICID™ (fidaxomicin) Tablets, an FDA approved antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). Optimer has filed a marketing authorization application with the European Medicines Agency for fidaxomicin. Optimer's clinical pipeline includes Pruvel™, a product in the fluoroquinolone class of antibiotics that has completed Phase 3 trials as a treatment for infectious diarrhea. Additional information can be found at

Optimer Pharmaceuticals, Inc.
David Walsey, Vice President, Investor Relations and Corporate Communications

Canale Communications, Inc.
Jason I. Spark, Senior Vice President

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Optimer Pharmaceuticals and Clinical Investigators to Present Data at Upcoming Medical Meetings
2. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
3. Optimer Pharmaceuticals, Inc. Announces Exercise in Full of Underwriters Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
4. Optimer Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
5. Optimer Pharmaceuticals to Present at Oppenheimer Healthcare Conference
6. Optimer Pharmaceuticals Announces Presentations at Upcoming IDSA Annual Meeting
7. Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC
8. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
9. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
10. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
11. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... SonaCare Medical, LLC, ... that it received de novo clearance from the U.S. Food and Drug Administration ... of prostate tissue. Sonablate® is the first High Intensity Therapeutic Ultrasound (HITU) device ...
(Date:10/12/2015)... (PRWEB) , ... October 12, 2015 , ... Spirax Sarco, ... the release of the CSM-C 600 compact clean steam generator . This ... that meets the requirements of HTM2031, HTM2010, and EN285 standards. The CMS-C 600 ...
(Date:10/12/2015)... ANNAPOLIS, Maryland , 12 de octubre de 2015 ... O. Matsui (D-CA) llegó a un récord en el ... tercera edición anual de la International Plasma Awareness Week ... octubre. La IPAW está patrocinada por la Plasma ... estando diseñada para: , Aumentar la ...
(Date:10/12/2015)... Belgium , Oct. 12, 2015 VolitionRx ... from a completed clinical study of its NuQ ® ... in the online issue of Clinical Epigenetics , the ... was conducted in collaboration with Lund ... Roland Andersson , MD, PhD, Professor of Surgery and Vice-Dean, ...
Breaking Biology Technology:
(Date:9/24/2015)... , September 24, 2015 ... 25 september 2015 Kerv ( ... digitala finanstjänster, lanserar idag världens första kontaktlösa ... samla in 77 000 GBP för massproduktion ... ) , Kerv-bärare ...
(Date:9/10/2015)... Sept. 10, 2015 Report Details ... quite delivered upon previous expectations of revenues, consumer adoption ... breakthrough year in which wearables begin to achieve that ... of the main reasons is the entrance of Apple ... the SmartWatches market, but the overall size of the ...
(Date:9/9/2015)... VANCOUVER, British Columbia , Sept. 9, 2015 ... achieved numerous organizational and solution-based milestones, furthering the ... the perils of online fraud. NuData ... key in enhancing the company,s growth cycle. The ... machine learning to determine good user behavior from ...
Breaking Biology News(10 mins):